The estimated Net Worth of Deepika Jalota is at least $72.4 millier dollars as of 15 September 2023. Dr Jalota owns over 4,104 units of Pmv Pharmaceuticals Inc stock worth over $45,218 and over the last 3 years he sold PMVP stock worth over $27,168.
Dr has made over 2 trades of the Pmv Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 4,104 units of PMVP stock worth $27,168 on 15 September 2023.
The largest trade he's ever made was selling 4,104 units of Pmv Pharmaceuticals Inc stock on 15 September 2023 worth over $27,168. On average, Dr trades about 1,000 units every 108 days since 2021. As of 15 September 2023 he still owns at least 29,946 units of Pmv Pharmaceuticals Inc stock.
You can see the complete history of Dr Jalota stock trades at the bottom of the page.
Dr. Deepika Jalota Pharm.D. is the Chief Regulatory & Quality Assurance Officer at Pmv Pharmaceuticals Inc.
Dr D is 44, he's been the Chief Regulatory & Quality Assurance Officer of Pmv Pharmaceuticals Inc since . There are 7 older and no younger executives at Pmv Pharmaceuticals Inc. The oldest executive at Pmv Pharmaceuticals Inc is Dr. Arnold J. Levine Ph.D., 81, who is the Co-Founder, Independent Director & Member of Scientific Advisory Board.
Deepika's mailing address filed with the SEC is C/O PMV PHARMACEUTICALS, INC., ONE RESEARCH WAY, PRINCETON, NJ, 08540.
Over the last 4 years, insiders at Pmv Pharmaceuticals Inc have traded over $56,359,813 worth of Pmv Pharmaceuticals Inc stock and bought 3,910,000 units worth $70,380,000 . The most active insiders traders include Peter A. Thompson, Capital Management, L.P.Kol... et Thilo Schroeder. On average, Pmv Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $130,810. The most recent stock trade was executed by Advisors Llc Orbi Med Capit... on 22 November 2023, trading 87,786 units of PMVP stock currently worth $195,763.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Pmv Pharmaceuticals Inc executives and other stock owners filed with the SEC include: